Clinical significance of MHC class II-associated invariant chain expression in human gastric carcinoma

Oncology Reports

Volumn 14, Issue 4, 2005, Pages 873-877

  Tamori, Yasuhiro ^a   Tan, Xiaodong ^a   Nakagawa, Kazuhiro ^a   Takai, Eiji ^a   Akagi, Junji ^a   Kageshita, Toshiro ^a   Egami, Hiroshi ^a   Ogawa, Michio ^a  

^a KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

Gastric carcinoma; MHC class II associated invariant chain; Prognosis; Tumor infiltrating lymphocytes

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ANTIGEN PRESENTATION; ARTICLE; CARCINOMA; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CHEMISTRY; FEMALE; GENE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; STOMACH TUMOR; TIME; TUMOR ASSOCIATED LEUKOCYTE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGEN PRESENTATION; ANTINEOPLASTIC AGENTS; CARCINOMA; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; FEMALE; GENES, MHC CLASS II; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; PROGNOSIS; STOMACH NEOPLASMS; TIME FACTORS;

EID: 33644816562     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.14.4.873     Document Type: Article

References (17)

1. Benacerraf B: Role of MHC gene products in immune regulation. Science 212: 1229-1238, 1981.
2. Kalams SA and Walker BD: The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med 188: 2199-2204, 1998. (Pubitemid 29028492)
3. Claesson L, Larhammer D, Rask L and Peterson PA: cDNA clone for the human invariant gamma chain of class II histocompatibility antigens and its implications for the protein structure. Proc Natl Acad Sci USA 80: 7395-7399, 1983. (Pubitemid 14178009)
4. Long EO, Strubin M, Wake CT, Gross N, Carrel S, Goodfellow P, Accolla RS and and Mach B: Isolation of cDNA clones for the p33 invariant chain associated with HLA-DR antigens. Proc Natl Acad Sci USA 80: 5714-5718, 1983. (Pubitemid 14249898)
5. Wolf PR and Ploegh HL: How MHC class II molecules acquire peptide cargo: biosynthesis and trafficking through the endocytic pathway. Annu Rev Cell Dev Biol 11: 267-306, 1995. (Pubitemid 26019606)
6. Ong GL, Goldenberg DM, Hansen HJ and Mattes MJ: Cell surface expression and metabolism of major histocompatibility complex class II invariant chain (CD74) by diverse cell lines. Immunology 98: 296-302, 1999. (Pubitemid 29487653)
7. Meazza R, Comes A, Orengo AM, Ferrini S and Accolla RS: Tumor rejection by gene transfer of the MHC class II transactivator in murine mammary adenocarcinoma cells. Eur J Immunol 33: 1183-1192, 2003. (Pubitemid 36609136)
8. + T lymphocytes by major histocompatibility complex class II tumor cell vaccines: a novel cell-based immunotherapy. Cancer Res 64: 1867-1874, 2004.
9. Japanese Gastric Cancer Association: Japanese Classification of Gastric Carcinoma. 13th edition. Kanehara Pub. Co., Tokyo, 1999.
10. Elliott EA, Drake JR, Amigorena S, Elsemore J, Webster P, Mellan I and Flavell RA: The invariant chain is required for intracellular transport and function of major histocompatibility complex class II molecules. J Exp Med 179: 681-694, 1994. (Pubitemid 24058756)
11. Cresswell P: Chemistry and functional role of the invariant chain. Curr Opin Immunol 4: 87-92, 1992.
12. Chamuleau ME, Sourwer Y, Van Ham SM, Zevenbergen A, Westers TM, Berkhof J, Meijer CJ, van de Loosdrecht AA and Ossenkoppele GJ: Class II-associated invariant chain peptide expression on myeloid leukemic blasts predicts poor clinical outcome. Cancer Res 64: 5546-5550, 2004. (Pubitemid 39095546)
13. Dissanayake SK, Tuera N and Ostrand-Rosenberg S: Presentation of endogenously synthesized MHC class II-restricted epitopes by class II cancer vaccine is independent of transporter associated with Ag processing and the proteosome. J Immunol 174: 1811-1819, 2005. (Pubitemid 40223920)
14. Ropponen KM, Eskelinen MJ, Lipponen PK, Alhava E and Kosma VM: Prognostic value of tumor-infiltrating lymphocytes (TILs) in colorectal cancer. J Pathol 182: 318-324, 1997. (Pubitemid 27285785)
15. Rossi HA, Liu Q, Banner B, Hsieh CC, Savas L and Savarese D: The prognostic value of invariant chain (Ii) and Her-2/neu expression in curatively resected colorectal cancer. Cancer J Sci Am 8: 268-275, 2002.
16. Zhao Y, Boczkowski D, Nair SK and Gilboa E: Inhibition of invariant chain expression in dendritic cells presenting endogenous antigens stimulates CD4+ T-cell responses and tumor immunity. Blood 102: 4137-4142, 2003. (Pubitemid 37486999)
17. Jiang Z, Xu M, Savas L, Clair PL and Banner BF: Invariant chain expression in colon neoplasms. Virchows Arch 435: 32-36, 1999. (Pubitemid 29346739)